VEGFA and hepatocellular carcinoma: The study conducted by Giovannini et al. 48 analyzed the pre-treatment percentage of PD-1+ granulocytes in blood of 34 HCC patients treated with PD-L1 ICI (atezolizumab) combined with VEGF inhibitor (bevacizumab) and ascertained that low PD-1+ granulocyte percentage (< 13%) was associated with longer mean time to progression (TTP) (NR vs. 3.2 months, P value < 0.0001) than high PD-1+ granulocyte percentage (≥ 13%).